We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Pattern Scan Laser improves Retinal Treatment Outcomes

By HospiMedica staff writers
Posted on 19 Feb 2008
An innovative laser system has been designed for the treatment of retinal diseases such as proliferative diabetic retinopathy, choroidal neovascularization, age-related macular degeneration, and retinal tears and detachments.

The PASCAL (Pattern Scan Laser) photocoagulator is intended for use in the treatment of ocular pathology, and is indicated for use in photocoagulation of both posterior and anterior segments including panretinal, focal, and macular grid photocoagulation. More...
The technology platform is based upon the use of a proprietary, semi-automated, pattern generation method employing short 532-nanometer laser pulses. This method of photocoagulation allows delivery of a predetermined pattern by scanning the placement of the laser spots and controlling the emission of the laser light. Up to five predetermined pattern types can be selected, including square arrays for panretinal photocoagulation; triple arcs for retinal tears, lattice degeneration and panretinal photocoagulation; and focal, full, and modified macular grids. The laser pulses are delivered in a rapid predetermined sequence resulting in improved precision, safety, patient comfort, and a significant reduction in treatment time compared with single-spot photocoagulation.

The fully integrated system incorporates an intuitive touch screen user interface, pattern scanner technology, an advanced optics slit lamp with a mounted micromanipulator, dual slit lamp mounted rotary power controls, proprietary PrecisionSpot laser delivery, a wheelchair accessible table, and other ergonomic features for both the physician and patient. The PASCAL photocoagulator is a product of OptiMedica (Santa Clara, CA, USA) and the winner of a gold medal at the 2007 Medical Design Excellence Awards.

Pre-clinical animal studies, as well as initial pilot studies in humans indicate that in addition to reducing treatment duration for typical patients with proliferative diabetic retinopathy, the number of sessions may also be reduced.


Related Links:
OptiMedica

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.